Intensity Therapeutics Inc (INTS)

May 05, 2026

Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN

May 05, 2026

May 05, 2026

Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - Newser

May 05, 2026

May 03, 2026

Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN

May 03, 2026

May 01, 2026

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore

May 01, 2026

May 01, 2026

INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill

May 01, 2026

Apr 30, 2026

Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan

Apr 30, 2026

Apr 27, 2026

Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29 - MSN

Apr 27, 2026

Apr 27, 2026

Why Is Retail Going Gaga Over INTS Stocks Today? - MSN

Apr 27, 2026

Apr 25, 2026

Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN

Apr 25, 2026

Apr 25, 2026

Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN

Apr 25, 2026

Apr 24, 2026

Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN

Apr 24, 2026

Apr 24, 2026

Intensity Therapeutics (INTS) Institutional Ownership 2026 $INTS - MarketBeat

Apr 24, 2026

Apr 23, 2026

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Aktiellt

Apr 23, 2026

Apr 17, 2026

Why Did INTS Stock Plummet 25% Today? - Dailyhunt

Apr 17, 2026

Apr 16, 2026

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Apr 16, 2026

Apr 15, 2026

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation - ADVFN

Apr 15, 2026

Apr 13, 2026

Support Test: Can Intensity Therapeutics Inc disrupt its industryGap Down & Long-Term Safe Investment Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart

Apr 10, 2026

Apr 10, 2026

Intratumoral Cancer Therapies Market: Expanding Revenue - openPR.com

Apr 10, 2026

Apr 10, 2026

Update Report: Is Intensity Therapeutics Inc likely to announce a buybackQuarterly Investment Review & Comprehensive Market Scan Reports - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Aug Technicals: Does Intensity Therapeutics Inc have a competitive edge2026 Trends & Expert Approved Trade Ideas - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Aug Fed Impact: Can Intensity Therapeutics Inc benefit from deglobalization2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

RSI Check: What are Intensity Therapeutics Incs recent SEC filings showingPortfolio Update Summary & Weekly Sector Rotation Insights - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Is Intensity (INTS) Stock Good for Passive Investors | Price at $5.49, Down 2.92%Verified Stock Signals - Newser

Apr 06, 2026

Mar 31, 2026

Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE) - The Globe and Mail

Mar 31, 2026

Mar 31, 2026

Hedge Fund Bets: What are Intensity Therapeutics Incs recent SEC filings showingMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 31, 2026

Risk Analysis: What is Intensity Therapeutics Incs debt to equity ratio2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Intensity Therapeutics (INTS) CEO receives 37,749-share stock bonus grant - Stock Titan

Mar 30, 2026

Mar 30, 2026

U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation - The Globe and Mail

Mar 30, 2026

Mar 28, 2026

Short Squeeze: Is Intensity Therapeutics Inc stock a top performer YTD2026 Momentum & Fast Gain Swing Trade Alerts - baoquankhu1.vn

Mar 28, 2026

Mar 28, 2026

Intensity Therapeutics, Inc. 2025 Annual Report: Innovative Intratumoral Cancer Drug Development and Clinical Pipeline Overview - Minichart

Mar 28, 2026

Mar 27, 2026

INTS: Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027 - TradingView

Mar 27, 2026

Mar 27, 2026

Clinical data and cash runway update for Intensity Therapeutics (NASDAQ: INTS) - Stock Titan

Mar 27, 2026

Mar 27, 2026

[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report - Stock Titan

Mar 27, 2026

Mar 27, 2026

INTS: Paused clinical trials and ongoing losses highlight urgent need for new funding - TradingView

Mar 27, 2026

Mar 27, 2026

Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 27, 2026

Mar 27, 2026

Market Pulse: Can Fury Gold Mines Limited expand its profit marginsEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 26, 2026

Mar 25, 2026

INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 25, 2026

Mar 25, 2026

US Market Recap: Does Intensity Therapeutics Inc have strong EBITDA margins2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn

Mar 25, 2026

Mar 25, 2026

Intensity Therapeutics receives new US patent for cancer treatment By Investing.com - Investing.com Australia

Mar 25, 2026

Mar 24, 2026

Intensity Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail

Mar 24, 2026

Mar 24, 2026

Intensity Therapeutics issued new patent in the US - TipRanks

Mar 24, 2026

Mar 24, 2026

Intensity Therapeutics receives new US patent for cancer treatment - Investing.com

Mar 24, 2026

Mar 24, 2026

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - Finviz

Mar 24, 2026